Neil has a 35 year track record as biotech entrepreneur, bringing multiple companies from foundation to IPO, trade-sale or sustained profitability. He is a co-founder of Alentis.
Prior to Alentis, Neil was from 2004 to 2017 co-founder & CEO of Evolva SA (synthetic biology), listing it on the Swiss stock exchange in 2009. Prior to Evolva Neil was co-founder of Topotarget (oncology) which listed in Copenhagen, and co-founder of Personal Chemistry (microwave chemistry) which is now listed on NASDAQ Stockholm as Biotage. Prior to this he played founding or early management roles in multiple companies in the UK, Scandinavia and USA, including Phytera, PNAD, Biacore and Scientific Generics. He formed his first company straight out of university in 1984.
Neil has a 1st class honours degree in Zoology from Oxford University. He is a board member of Unibio and Double Bioventures, an advisor to The Novo Foundation’s BioInnovation Institute and strategy director of Baselaunch.
General Partner at BioMedPartners. Former Head of Roche Clinical Research & Exploratory Development and Head of the Cardiovascular & Metabolism Research. Member of the Global R&D Leadership team for more than 12 years at F. Hoffmann-La Roche Ltd.
Managing Partner at BB Pureos Bioventures. He has been an active venture capitalist since the late 90’s, investing in life science companies across all stages and types. Martin’s past and current board assignments include BB’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan and Glycart. PhD Protein Chemist & Biochemist.
Senior Investment Manager at Bpifrance. Since 2014, he has been involved in a dozen investment deals and current board member positions include Dynacure and Igyxos. Prior, he gained experience in various biotech roles, co-discovered a vaccine candidate, developed an antibody production service. He holds an MSc in Biotechnology Engineering from the University of Technology of Compiègne (UTC), a PhD in immunology and an executive Master in Finance.
Thomas is the scientific founder of Alentis. He holds a chair in hepatology at the University of Strasbourg and is head of the Inserm Institute for Viral and Liver Disease. He is a physician scientist with 25+ years experience in translational research in liver disease.
Prior to Strasbourg Thomas held positions at the Massachusetts General Hospital, Harvard Medical School, the US National Institutes of Health, the Broad Institute and the University Hospitals of Freiburg and Munich. He is an inventor on 15 patent families and the author of 300+ publications. He holds multiple international scientific awards, and is a recipient of the Prix Galien for drug discovery.
Thomas undertook research and clinical training at German Cancer Research Center, Heidelberg; University of Munich; Gastrointestinal Unit, Massachusetts General Hospital, Boston; US National Institutes of Health, NIDDK Liver Disease Branch, Bethesda. He is a board-certified gastroenterologist and internist and has an MD from the University of Heidelberg.